Fresh Tracks Therapeutics, Inc. (FRTX)

NASDAQ: FRTX · IEX Real-Time Price · USD
2.05
0.00 (0.00%)
At close: Oct 5, 2022 12:00 AM
2.08
+0.03 (1.46%)
null: Oct 6, 2022 8:54 AM EDT
0.00%
Market Cap 5.64M
Revenue (ttm) 4.64M
Net Income (ttm) -29.88M
Shares Out 2.75M
EPS (ttm) -12.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date Jul 5, 2022
Volume 8,659
Open 2.08
Previous Close 2.05
Day's Range 1.92 - 2.10
52-Week Range 1.67 - 34.20
Beta 0.11
Analysts Buy
Price Target 18.19 (+787.3%)
Earnings Date Nov 7, 2022

About FRTX

Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potent... [Read more...]

Industry Biotechnology
Founded 2009
CEO Robert Brown
Employees 16
Stock Exchange NASDAQ
Ticker Symbol FRTX
Full Company Profile

Financial Performance

In 2021, FRTX's revenue was $404,000, a decrease of -77.83% compared to the previous year's $1.82 million. Losses were -$39.47 million, 88.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for FRTX stock is "Buy." The 12-month stock price forecast is 18.19, which is an increase of 787.32% from the latest price.

Price Target
$18.19
(787.32% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02

FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD cohorts dosing

3 weeks ago - GlobeNewsWire

Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics

New name, logo, website, and branding reflect the Company's strategic shift toward developing potentially groundbreaking autoimmune and inflammatory disease therapies

4 weeks ago - GlobeNewsWire

Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month

1 month ago - GlobeNewsWire

Will Brickell (BBI) Report Negative Earnings Next Week? What You Should Know

Brickell (BBI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022

BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative ...

2 months ago - GlobeNewsWire

Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

BOULDER, Colo., July 20, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative ...

2 months ago - GlobeNewsWire

Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022

BOULDER, Colo., July 06, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by devel...

3 months ago - GlobeNewsWire

Brickell Biotech Announces 1-For-45 Reverse Stock Split

Common stock will begin trading on a split-adjusted basis on July 5, 2022 Common stock will begin trading on a split-adjusted basis on July 5, 2022

3 months ago - GlobeNewsWire

Brickell Biotech (BBI) Stock Gains 50% Ahead of Meeting to Prevent Delisting

Delistings are commonplace in this bear market, however investors in Brickell Biotech and BBI stock are cheering some news today. The post Brickell Biotech (BBI) Stock Gains 50% Ahead of Meeting to Prev...

3 months ago - InvestorPlace

Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02

– BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad potential to treat debilitating autoimmune and inflammatory diseases –

4 months ago - GlobeNewsWire

Brickell (BBI) Reports Q1 Loss, Lags Revenue Estimates

Brickell (BBI) delivered earnings and revenue surprises of -33.33% and 52.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Brickell Biotech Reports First Quarter 2022 Financial Results and Provides Corporate Update

Completed sale of sofpironium bromide to Botanix Pharmaceuticals for up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and sa...

4 months ago - GlobeNewsWire

Brickell Biotech to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12, 2022

BOULDER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by develo...

5 months ago - GlobeNewsWire

Brickell Biotech Shares Surge After Offloading Late-Stage Asset To Australia-Based Firm

Brickell Biotech Inc (NASDAQ: BBI) agreed to sell sofpironium bromide rights to Australia-based Botanix Pharmaceuticals Limited. Brickell will receive upfront and potential near-term regulatory mileston...

5 months ago - Benzinga

Brickell Biotech Announces Adjournment of Annual Meeting of Stockholders

Meeting adjourned to May 17, 2022 at 10 a.m. MT

5 months ago - GlobeNewsWire

Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals

Deal includes up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and sales milestone payments, plus tiered earn out payments o...

5 months ago - GlobeNewsWire

Has Brickell Biotech (BBI) Outpaced Other Medical Stocks This Year?

Here is how Brickell (BBI) and Eli Lilly (LLY) have performed compared to their sector so far this year.

5 months ago - Zacks Investment Research

Brickell (BBI) Reports Q4 Loss, Misses Revenue Estimates

Brickell (BBI) delivered earnings and revenue surprises of 33.33% and 49.52%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Brickell Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Broadened strategic focus and expanded pipeline in immunology and inflammation following acquisition of rights to BBI-02, a potential first-in-class oral DYRK1A inhibitor, a portfolio of novel STING inh...

6 months ago - GlobeNewsWire

Brickell Biotech Selected for a Late-Breaking Oral Presentation of US Phase 3 Pivotal Cardigan I and Cardigan II Stud...

BOULDER, Colo., March 10, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by deve...

6 months ago - GlobeNewsWire

Brickell Biotech to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on Marc...

BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by deve...

6 months ago - GlobeNewsWire

Brickell Biotech, Carna Biosciences Ink Licensing Pact For STING inhibitors

Brickell Biotech Inc BBI has entered into an exclusive agreement with Carna Biosciences Inc to develop and commercialize Carna's portfolio of oral Stimulator Interferon Genes (STING) antagonists.  Thous...

8 months ago - Benzinga

Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inf...

Lead STING inhibitor candidate, BBI-10, demonstrated dose-dependent cytokine reduction in nonclinical in vitro and in vivo studies providing strong proof-of-mechanism

8 months ago - GlobeNewsWire

Brickell (BBI) Reports Q3 Loss, Misses Revenue Estimates

Brickell (BBI) delivered earnings and revenue surprises of -45.45% and -56.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Announced positive topline results from the Phase 3 pivotal clinical studies of sofpironium bromide gel, 15% in primary axillary hyperhidrosis patients; plan to submit a New Drug Application (NDA) to th...

10 months ago - GlobeNewsWire